Companies press releases
May 10, 2018, 04:30 ET CRANBURY, N.J., May 10, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2018 operating results on Tuesday, May 15, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management […]
PL-8177 Evaluated in Animal Models of Inflammatory Bowel Disease and Autoimmune Uveitis; PL-8331 Evaluated in an Animal Model of Dry Eye CRANBURY, N.J., May 9, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential,
CRANBURY, N.J., April 3, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced the presentation of a poster on preclinical studies of an oral formulation of PL-8177, a selective melanocortin receptor 1
Feb 12, 2018, 07:30 ET CRANBURY, N.J., Feb. 12, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2017. Recent Highlights Bremelanotide – Under development
Feb 07, 2018, 04:00 ET CRANBURY, N.J., Feb. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2018 operating results on Monday, February 12, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its
CRANBURY, N.J., Feb. 5, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the first healthy subjects have been dosed in a Phase 1 clinical study of PL-8177. The Phase 1
CRANBURY, N.J., Jan. 3, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the U.S. Food and Drug Administration (FDA) has notified Palatin that it may proceed with its clinical investigation of
Palatin to Receive $500,000 Upfront Entitled to Receive $3.0 Million on First Commercial Sale in Korea and Up to $37.5 Million in Sales Related Milestones plus Royalties on Net Sales Nov 21, 2017, 06:30 ET CRANBURY, N.J., Nov. 21, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into
CRANBURY, N.J., Nov. 13, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2017. Recent Highlights Bremelanotide – Under development for Hypoactive Sexual Desire Disorder
CRANBURY, N.J., Nov. 8, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2018 operating results on Monday, November 13, 2017 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 13,
